DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Aaron Berg, Amarin’s Interim President and Chief Executive Officer and Tom Reilly, Amarin’s Chief Financial Officer, will present at two upcoming investor conferences:

-- VASCEPA Approved by the National Medical Products Administration (NMPA) as an Adjunct to Diet to Reduce Triglyceride Levels in Adult Patients with Severe Hypertriglyceridemia (≥ 500 mg/dL) -- -- EddingPharm Now Working Towards Preparing for Commercial Launch of VASCEPA Across Mainland China

-- VASCEPA Approved by the National Medical Products Administration (NMPA) as an Adjunct to Diet to Reduce Triglyceride Levels in Adult Patients with Severe Hypertriglyceridemia (≥ 500 mg/dL) -- -- EddingPharm Now Working Towards Preparing for Commercial Launch of VASCEPA Across Mainland China

— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — --Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action-- DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Amarin

— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — --Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action-- DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Amarin